In a report released on November 8, Marc Goodman from SVB Securities maintained a Buy rating on Aptinyx (APTX – Research Report), with a price target of $2.00. The company’s shares closed yesterday at $0.27.
According to TipRanks, Goodman is an analyst with an average return of -1.0% and a 41.53% success rate. Goodman covers the Healthcare sector, focusing on stocks such as Amylyx Pharmaceuticals Inc, Axsome Therapeutics, and Biogen.
Currently, the analyst consensus on Aptinyx is a Moderate Buy with an average price target of $1.67, implying a 511.95% upside from current levels. In a report released yesterday, BMO Capital also maintained a Buy rating on the stock with a $2.00 price target.
See the top stocks recommended by analysts >>
The company has a one-year high of $3.76 and a one-year low of $0.20. Currently, Aptinyx has an average volume of 421.4K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aptinyx Inc. is a clinical stage biopharmaceutical company. It engages in the discovery, development, and and commercialization of transformative therapies for disorders of the brain and nervous system. Its product includes NYX-2925, NYX-783, NYX-458, and the AGN-241751 program. The company was founded by Norbert G. Riedel and Joseph R. Moskal in June 2015 and is headquartered in Evanston, IL.
